Back to top
more

Bausch Health Cos Inc. (BHC)

(Delayed Data from NYSE)

$23.52 USD

23.52
1,577,186

-0.15 (-0.63%)

Updated May 24, 2019 03:57 PM ET

Add to portfolio

2-Buy   2      

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
25.08%
18.07%
9.73%
5.25%
2.19%
10.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

A Value | C Growth | A Momentum | A VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Is Bausch Health Cos (BHC) Stock Outpacing Its Medical Peers This Year?

Is (BHC) Outperforming Other Medical Stocks This Year?

BHC

Zacks Equity Research

Is Bausch Health (BHC) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

BHC

Zacks Equity Research

All You Need to Know About Bausch (BHC) Rating Upgrade to Buy

Bausch (BHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BHC

Zacks Equity Research

Aerie (AERI) Q1 Earnings Beat, Rhopressa Misses Estimates

Aerie (AERI) reports narrower-than-expected Q1 loss. However, Rhopressa lags expectations.

PFE BMY AERI BHC

Zacks Equity Research

Options Traders Expect Huge Moves in Bausch Health (BHC) Stock

Investors need to pay close attention to Bausch Health (BHC) stock based on the movements in the options market lately.

BHC

Zacks Equity Research

Bausch's (BHC) Q1 Earnings Beat Estimates, Revenues Miss

Bausch (BHC) Q1 earnings surpass estimates, while revenues miss the same. The increase in guidance was impressive.

BMY RHHBY BHC ETON

Zacks Equity Research

Bausch Health (BHC) Q1 Earnings Top Estimates

Bausch (BHC) delivered earnings and revenue surprises of 15.73% and -1.19%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

BHC

Zacks Equity Research

What's in the Cards for Bausch Health (BHC) Q1 Earnings?

Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q1 results on May 6.

GILD ADRO MNK BHC

Zacks Equity Research

Bausch Health (BHC) Reports Next Week: What Awaits?

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BHC

Zacks Equity Research

Is Bausch Health (BHC) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

BHC

Zacks Equity Research

Dr. Reddy's (RDY) Inks Deal to Acquire Portfolio of 42 ANDAs

Dr. Reddy's (RDY) inks agreement to acquire the yet-to-be-marketed portfolio of 42 non-marketed Abbreviated New Drug Applications (ANDAs) in the United States.

MNK RDY EVOK BHC

Zacks Equity Research

Is Bausch Health (BHC) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

BHC

Zacks Equity Research

All You Need to Know About Bausch (BHC) Rating Upgrade to Buy

Bausch (BHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

BHC

Zacks Equity Research

Aerie (AERI) Improves 22% YTD: Is Momentum Likely to Sustain?

Aerie (AERI) gains momentum on the back of the FDA approval of its second drug, Rocklatan.

NVS AGN AERI BHC

Zacks Equity Research

Aldeyra's Eye Drug Meets Main Goal in Study, Shares Surge

Aldeyra (ALDX) announced positive top-line data from a phase III study on pipeline product, reproxalap topical ophthalmic solution in patients with allergic conjunctivitis.

AZN RHHBY ALDX BHC

Zacks Equity Research

Why Is Bausch (BHC) Up 8.3% Since Last Earnings Report?

Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BHC

Zacks Equity Research

Is Bausch Health Companies (BHC) a Great Stock for Value Investors?

Is Bausch Health Companies (BHC) a great pick from the value investor's perspective right now? Read on to know more.

BHC

Zacks Equity Research

Aerie (AERI) Q4 Earnings Miss, Rhopressa Gains Traction

Aerie (AERI) reports wider-than-expected Q4 loss. Nevertheless, Rhopressa's sales beat estimates as demand picks up.

PFE CELG AERI BHC

Zacks Equity Research

Bausch (BHC) Q4 Earnings Beat Estimates, Revenues Down Y/Y

Bausch (BHC) Q4 earnings and revenues surpass estimates. However, guidance for 2019 is not impressive.

GSK BMY BHC ETON

Zacks Equity Research

Bausch Health (BHC) Surpasses Q4 Earnings and Revenue Estimates

Bausch (BHC) delivered earnings and revenue surprises of 19.32% and 1.33%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

BHC

Zacks Equity Research

What's in the Cards for Bausch Health (BHC) Q4 Earnings?

Investors are looking forward to Salix and Bausch+Lomb's performance, and other pipeline updates when Bausch (BHC) reports Q4 results on Feb 20.

ACAD REPH MNK BHC

Zacks Equity Research

Earnings Preview: Bausch Health (BHC) Q4 Earnings Expected to Decline

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BHC

Zacks Equity Research

Bausch (BHC) Upgraded to Strong Buy: Here's Why

Bausch (BHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

BHC

Tirthankar Chakraborty

New Strong Buy Stocks for February 5th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday

MESA HRB BTU BHC AVH

Zacks Equity Research

Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?

Alexion's key drug like Soliris should drive growth in the fourth quarter of 2018.

REGN ALXN HALO BHC